跳到正文
Longevity.Technology (@LongevityTech)· LongevityTech·· 24 天前评分6

Mission Therapeutics启动MTX325的1b期试验

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in the brain.

导读

Mission Therapeutics已启动一项36名患者的1b期研究,测试MTX325,该药物旨在清除大脑中受损的线粒体。 https://vist.ly/5qhdn #longevity #geroscience #MissionTherapeutics #MTX325 #mitochondria

来源:Longevity.Technology (@LongevityTech) · x.com